Compare Li Auto Inc (LI) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs Zoetis Inc — how do they compare? Li Auto Inc trades at $11.54 (market cap $10.71B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 2.8× Li Auto Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Li Auto Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Li Auto Inc for 101 Days and Zoetis Inc for 70 Days on average.
| LI | ZTS | |
|---|---|---|
Market Cap | $10.71B | $30.20B |
Volume | 1,781,143 | 6,175,327 |
Sector | Consumer Cyclical | Health |
52-Week High | $23.61 | $147.53 |
52-Week Low | $10.69 | $69.09 |
Typical Hold Time | 101 Days | 70 Days |
Enterprise Value | $139.58M | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $10.90, down 0.82% and near 52-week lows amid delivery moderation concerns. The stock shows bearish technical signals with negative moving averages and neutral oscillators. Fundamentally, revenue declined to $112.31B in 2025 with net income of $1.12B, though recent quarterly earnings missed expectations. Analyst sentiment is mixed with 44% buy ratings but a consensus price target of $15.18, suggesting 39% upside potential from current levels.
The outlook remains challenging with competitive pressures and cash flow concerns, but the company's strong balance sheet ($112.81B cash) provides cushion. New model launches (Li i9, MEGA) and global expansion could drive recovery, though execution risks and China's auto market weakness pose headwinds. The stock appears undervalued on P/S (0.73) and EV/EBITDA (1.72) metrics relative to growth potential.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
